Herein described are solid oral compositions of dyes for use in diagnostic endoscopy, preferably colon endoscopy.

Provided herein are encapsulated liposomes comprising a lipid bilayer, a first polyethylene glycol (PEG) corona, a targeting molecule and a second PEG corona. The second, encapsulating PEG corona can be reversibly linked to the first PEG corona. Also provided are pharmaceutical compositions comprising the encapsulated liposomes and methods of treating a subject with a disease characterized by production of reactive oxygen species (ROS) with the compositions. Also provided are methods of making the encapsulated liposomes disclosed herein.

The present invention provides compositions relating to nanoparticles, such as nanocapsules, that selectively target cells associated with diseases or disorders (e.g., cancer cells). The present invention further relates to methods relating to the said nanoparticles for imaging, detection, and treatment of diseases or disorders in a subject. The present invention additionally provides kits that find use in the practice of the methods of the invention.

Provided is a conjugate for photodynamic diagnosis or treatment in which a peptide binds with a photosensitizer via an intracellularly degradable linkage, and a composition for photodynamic diagnosis or treatment including the same. The conjugate generates no fluorescent signal and reactive oxygen in normal tissues or during the circulation in the blood by quenching a fluorescent signal and reactive oxygen generation ability of the photosensitizer. After the conjugate is selectively absorbed into target cells, a linker is degraded in cells to increase the distance between tryptophan included in the peptide and the photosensitizer, and the quenching action is terminated to generate a strong fluorescence signal and induce active generation of reactive oxygen. The conjugate has high tissue permeability, shows a high photodynamic therapeutic effect in only target cells while being safe in normal cells, and can obtain a good diagnostic image having a high ratio of target signal to background.

Disclosed are biomimetic proteolipid nanovesicles that possess remarkable properties for targeting compounds of interest to particular mammalian cell and tissue types. In particular embodiments, drug delivery vehicles are provided composed of synthetic phospholipids and cholesterol, enriched of leukocyte membranes, and surrounding an aqueous core. These nanovesicles are able to both avoid the immune system, thanks to the presence on their surface of self-tolerance proteins, as CD-45, CD-47, and MHC-1, and target inflamed endothelium, thereby diffusing in the tumor microenvironment. These properties make the composition highly suited for targeted drug delivery to mammalian tumor cells in vitro and in situ.

Disclosed are cell membrane-derived nanovesicles, a method of preparing the nanovesicles, and a pharmaceutical composition and a diagnostic kit using the nanovesicles. The cell membrane-derived nanovesicles may prevent potential adverse effects because intracellular materials (e.g., genetic materials and cytosolic proteins) unnecessary for delivering therapeutic or diagnostic substances are removed from the nanovesicles. In addition, as the nanovesicles may be targeted to specific cells or tissues, therapeutic or diagnostic substances may be predominantly delivered to the targeted cells or tissues, while delivery of the substances may be inhibited. Therefore, the nanovesicles may alleviate suffering and inconvenience of patients by reducing adverse effects of therapeutic substances and by improving efficacy of the substances. In addition, the cell membrane-derived nanovesicles loaded with therapeutic or diagnostic substances and a method of preparing the nanovesicles may be used in vitro or in vivo for therapeutic or diagnostic purposes, or for experimental use.

Nanolipoprotein particles having at least a scaffold protein component and a membrane lipid component and related compositions, methods and systems are described. The membrane lipid component includes at least one or more membrane forming lipids, one or more polymerized lipids and/or one or more polymerizable lipids.

Disclosed are methods for designing and manufacturing biomimetic proteolipid nanovesicles using a microfluidic approach, and in particular, a NanoAssemblr-based platform, which allows for the high-throughput, reproducible, and scalable production of nanoparticles, without affecting their pharmaceutical and biological properties. These nanovesicles, which are composed of synthetic phospholipids and cholesterol, enriched of leukocyte membranes, and surrounding an aqueous core, possess remarkable properties for targeting compounds of interest to particular mammalian cell and tissue types.

Provided herein are encapsulated liposomes comprising a lipid bilayer, a first polyethylene glycol (PEG) corona, a targeting molecule and a second PEG corona. The second, encapsulating PEG corona can be reversibly linked to the first PEG corona. Also provided are pharmaceutical compositions comprising the encapsulated liposomes and methods of treating a subject with a disease characterized by production of reactive oxygen species (ROS) with the compositions. Also provided are methods of making the encapsulated liposomes disclosed herein.

Disclosed are cell membrane-derived nanovesicles, a method of preparing the nanovesicles, and a pharmaceutical composition and a diagnostic kit using the nanovesicles. The cell membrane-derived nanovesicles may prevent potential adverse effects because intracellular materials (e.g., genetic materials and cytosolic proteins) unnecessary for delivering therapeutic or diagnostic substances are removed from the nanovesicles. In addition, as the nanovesicles may be targeted to specific cells or tissues, therapeutic or diagnostic substances may be predominantly delivered to the targeted cells or tissues, while delivery of the substances may be inhibited. Therefore, the nanovesicles may alleviate suffering and inconvenience of patients by reducing adverse effects of therapeutic substances and by improving efficacy of the substances. In addition, the cell membrane-derived nanovesicles loaded with therapeutic or diagnostic substances and a method of preparing the nanovesicles may be used in vitro or in vivo for therapeutic or diagnostic purposes, or for experimental use.